NICE backs Takeda’s Alunbrig in second-line lung cancer

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Feb 16, 2019 at 12:12 AM.

  1. #1 cafead, Feb 16, 2019 at 12:12 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,990
    Likes Received:
    3
    via NICE has published final draft guidance recommending regular NHS funding in England for Takeda’s Alunbrig (brigatinib), for ALK-positive advanced non-small cell lung cancer, in patients already treated with Pfizer’s Xalkori.

    article source
     
    Quote

Reply to Thread